NCT04164199 2026-03-16
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
BeOne Medicines
Phase 3 Enrolling by invitation
Clinical Trials
141 trialsNCT05109728 2026-03-16
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Novartis
Phase 1 Active not recruiting
NCT06556563 2026-03-13
EF-41
NovoCure Ltd.
Phase 3 Recruiting
NCT05417594 2026-03-12
CERTIS1
AstraZeneca
Phase 1/2 Recruiting
NCT05440786 2026-03-12
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Eli Lilly and Company
Phase 2 Active not recruiting
NCT07297212 2026-03-12
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
Phase 2 Recruiting
NCT07015242 2026-03-11
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2 Recruiting
NCT07195591 2026-03-04
BRIDGES
GT Medical Technologies, Inc.
Phase 3 Recruiting
NCT07310784 2026-03-03
A Phase II Trial of LM103 in Advanced Melanoma
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 2 Recruiting
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT06346067 2026-02-27
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Erasca, Inc.
Phase 3 Active not recruiting
NCT06805305 2026-02-23
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Diakonos Oncology Corporation
Phase 2 Recruiting
NCT04478279 2026-02-09
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
Phase 1/2 Active not recruiting
NCT05739942 2026-02-03
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
Novartis
Phase 1 Active not recruiting
NCT03491683 2026-01-28
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Inovio Pharmaceuticals
Phase 1/2 Active not recruiting
NCT04752813 2026-01-26
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
BPGbio
Phase 2 Active not recruiting
NCT07365280 2026-01-26
Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma
ZSky Biotech Inc
Phase 2 Not yet recruiting
NCT06105619 2026-01-20
A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
Beijing Pearl Biotechnology Limited Liability Company
Phase 2/3 Active not recruiting
NCT07349693 2026-01-20
Cerebraca-02/3
Everfront Biotech Co., Ltd.
Phase 2/3 Not yet recruiting
NCT06931626 2025-11-12
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
Nerviano Medical Sciences
Phase 1 Recruiting
NCT05902169 2025-11-10
SONOBIRD
CarThera
Phase 3 Active not recruiting
NCT04373785 2025-10-21
NG101m Adjuvant Therapy in Glioblastoma Patients
NeuGATE Theranostics
Phase 1/2 Not yet recruiting
NCT05429502 2025-10-10
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Novartis
Phase 1 Terminated
NCT04337177 2025-09-23
Flavored, Oral Irinotecan VAL-413 (OrotecanĀ®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies, LLC
Phase 1 Recruiting
NCT04919226 2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT06624644 2025-09-10
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics, Inc.
Phase 2/3 Recruiting
NCT01107522 2025-09-09
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With TemodarĀ® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With TemodarĀ® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Tactical Therapeutics, Inc.
Phase 1 Unknown
NCT04587830 2025-08-26
GBM
Polaris Group
Phase 2 Active not recruiting
NCT04910022 2025-08-19
Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
Nerviano Medical Sciences
Phase 1/2 Active not recruiting
NCT07120984 2025-08-13
IMAGLIO
Philogen S.p.A.
Phase 2 Not yet recruiting
NCT04388475 2025-08-12
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
Oblato, Inc.
Phase 2 Completed
NCT04239092 2025-07-17
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Actuate Therapeutics Inc.
Phase 1 Terminated
NCT02667587 2025-06-18
CheckMate548
Bristol-Myers Squibb
Phase 3 Completed
NCT02655601 2025-06-08
BMX-HGG
BioMimetix JV, LLC
Phase 1/2 Completed
NCT04566380 2025-06-03
ONO-4538 Phase II Rollover Study (ONO-4538-98)
Ono Pharmaceutical Co. Ltd
Phase 2 Recruiting
NCT03782415 2025-05-21
Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma
MediciNova
Phase 1/2 Completed
NCT06161974 2025-02-21
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
Phase 2 Recruiting
NCT03709680 2025-01-14
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Pfizer
Phase 2 Active not recruiting
NCT04421378 2024-12-16
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics Inc
Phase 1/2 Terminated
NCT06012695 2024-11-14
NBM-BMX Administered Orally to Patients with Solid Tumors or Newly Diagnosed Glioblastoma
Novelwise Pharmaceutical Corporation
Phase 1/2 Recruiting
NCT04525014 2024-10-31
PIRATE
EpicentRx, Inc.
Phase 1 Terminated
NCT01127178 2024-10-10
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Eisai Inc.
Phase 1 Terminated
NCT04434482 2024-09-19
IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
Impact Therapeutics, Inc.
Phase 1/2 Completed
NCT06595186 2024-09-19
JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
JenKem Technology Co., Ltd.
Phase 2 Recruiting
NCT06353360 2024-08-09
TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Phase 2 Recruiting
NCT03776071 2024-04-22
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
Denovo Biopharma LLC
Phase 3 Completed
NCT02880410 2024-04-12
FLAG
Monteris Medical
Phase 1 Terminated
NCT00589875 2024-04-03
BrTK02
Candel Therapeutics, Inc.
Phase 2 Completed
NCT02052648 2024-03-27
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Lumos Pharma
Phase 1/2 Completed
NCT02315534 2023-11-15
A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
Sumitomo Pharma America, Inc.
Phase 1/2 Completed